Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 12099

1.

Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.

Kim EA, Kim YH, Kang HW, Yoon HY, Kim WT, Kim YJ, Yun SJ, Moon SK, Choi YH, Kim IY, Lee SC, Kim WJ.

J Korean Med Sci. 2015 Jul;30(7):937-42. doi: 10.3346/jkms.2015.30.7.937. Epub 2015 Jun 10.

2.

Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols.

Kang HW, Lee JY, Kwon JK, Jeh SU, Jung HD, Cho KS, Ham WS, Choi YD.

J Korean Med Sci. 2015 Jul;30(7):932-6. doi: 10.3346/jkms.2015.30.7.932. Epub 2015 Jun 10.

3.

Comparison of perioperative outcomes between running versus interrupted vesicourethral anastomosis in open radical prostatectomy: A single-surgeon experience.

Lim JH, Park CM, Kim HK, Park JY.

Korean J Urol. 2015 Jun;56(6):443-8. doi: 10.4111/kju.2015.56.6.443. Epub 2015 Jun 1.

4.

Current role of multiparametric magnetic resonance imaging in the management of prostate cancer.

Katelaris NC, Bolton DM, Weerakoon M, Toner L, Katelaris PM, Lawrentschuk N.

Korean J Urol. 2015 May;56(5):337-345. Epub 2015 Apr 6. Review.

5.

The need for a personalized approach for prostate cancer management.

Sedelaar JP, Schalken JA.

BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.

6.

Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.

Park HK, Kim H, Kim HG, Cho YM, Jung WY, Han HS, Hwang TS, Kwon GY, Lim SD.

J Korean Med Sci. 2015 May;30(5):533-41. doi: 10.3346/jkms.2015.30.5.533. Epub 2015 Apr 15.

7.
8.

Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.

Nowroozi M, Ayati M, Jamshidian H, Arbab A, Ghorbani H, Amini E, Hakima H, Salehi S, Ghadian A.

Nephrourol Mon. 2015 Mar 20;7(2):e26752. doi: 10.5812/numonthly.26752. eCollection 2015 Mar.

9.

High-Intensity Focused Ultrasound (HIFU) in Localized Prostate Cancer Treatment.

Alkhorayef M, Mahmoud MZ, Alzimami KS, Sulieman A, Fagiri MA.

Pol J Radiol. 2015 Mar 13;80:131-41. doi: 10.12659/PJR.892341. eCollection 2015. Review.

10.

Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-response meta-analysis of prospective cohort studies.

Fu YQ, Zheng JS, Yang B, Li D.

J Epidemiol. 2015;25(4):261-74. doi: 10.2188/jea.JE20140120. Epub 2015 Mar 14. Review.

11.

Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean.

Bae JM.

Epidemiol Health. 2015 Mar 7;37:e2015015. doi: 10.4178/epih/e2015015. eCollection 2015.

12.

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3776-81. doi: 10.1073/pnas.1500128112. Epub 2015 Mar 11.

13.

Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study.

Beebe-Dimmer JL, Yee C, Cote ML, Petrucelli N, Palmer N, Bock C, Lane D, Agalliu I, Stefanick ML, Simon MS.

Cancer. 2015 Apr 15;121(8):1265-72. doi: 10.1002/cncr.29075. Epub 2015 Mar 9.

14.

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap.

Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB.

Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.

15.

People's willingness to accept overdetection in cancer screening: population survey.

Van den Bruel A, Jones C, Yang Y, Oke J, Hewitson P.

BMJ. 2015 Mar 3;350:h980. doi: 10.1136/bmj.h980.

16.

Stage at diagnosis and early mortality from cancer in England.

McPhail S, Johnson S, Greenberg D, Peake M, Rous B.

Br J Cancer. 2015 Mar 31;112 Suppl 1:S108-15. doi: 10.1038/bjc.2015.49.

17.

Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.

Lee HW, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

J Korean Med Sci. 2015 Mar;30(3):317-22. doi: 10.3346/jkms.2015.30.3.317. Epub 2015 Feb 16.

18.

Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer.

You SH, Lee JY, Lee CG.

Yonsei Med J. 2015 Mar;56(2):510-8. doi: 10.3349/ymj.2015.56.2.510.

20.

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.

Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2515-20. doi: 10.1073/pnas.1500097112. Epub 2015 Feb 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk